索拉非尼治疗肝细胞癌进展后的二线治疗

原发性肝癌是临床最常见的恶性肿瘤之一，其病理分型绝大多数属于肝细胞癌（HCC）。索拉非尼是第一个亦是目前唯一一个被多个国家批准用于治疗HCC的分子靶向药物，但其疗效有限，多数患者口服一段时间后会出现耐药而病情进展，对于这些患者目前尚缺乏标准的二线治疗方案，本文就索拉非尼治疗HCC耐药后的最新二线治疗研究进展作一综述。

Second-line therapy for patients with hepatocellular carcinoma resisting to sorafenib

Primary hepatocarcinoma is one of the most common malignancies in clinic,of which the most common pathological type is hepatocellular carcinoma（ HCC）. Sorafenib is the first and also the only molecular targeted drug approved in many countries for the treatment of HCC,but its efficacy is limited. After taking the drug for a period,most patients emerge disease progression because of resistance to the drug. Currently,the standard second-line treatment isn＇t available for these patients. This article reviews the latest research progress of second-line therapy for the HCC patients resisting to sorafenib.